Fig. 6

Immune cell recruitment to tumors and spleens treated with anti-Ly6G. Percentage of CD45+ immune cells (a), Ly6G+ neutrophils (b), F4/80+ macrophages (c), and CD3+ T cells (d) in wild-type (WT) and collagen-dense (COL) mammary tumors from 12-week-old mice treated with control IgG or Ly6G (n = 5–6) obtained by flow cytometry at day 24 of the treatment regimen (described in Fig. 5a). Immunohistochemistry of tumors from the four treatment groups (e). Tumors were stained with Ly6G (1A8) in DAB and counterstained with hematoxylin. Scare bar = 100 um. Average number of Ly6G+ cells found in eight fields of view per tumor slide (n = 3) (f). Percentage of CD45+ immune cells (g), Ly6G+ neutrophils (h), F4/80+ macrophages (i), and CD3+ T-cells (j) in spleens of the same treated and untreated WT and COL mice, as shown in a–d